drugset / Trial / NCT01214291

Efficacy and Safety Study of Toremifene Citrate for the Reduction in the Risk of New Bone Fracture Occurrences in Men With Prostate Cancer

NCT01214291

Phase 3 Withdrawn GTx Ipsen · collab
RandomizedParallel-groupTriple-blindPrevention

Summary

The purpose of this study is to determine whether Toremifene Citrate is effective in reducing the risk of bone fractures in men with prostate cancer who are on Androgen Deprivation Therapy.

Timeline

Start
2011-03
Primary completion
2011-09
Completion
2011-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Toremifene Small molecule 80 mg

Indications